Loading organizations...
San Diego, California-based Aizen Therapeutics is an artificial intelligence-native biotechnology company that designs oral peptides to treat chronic immune disorders. The enterprise utilizes its proprietary DaX platform, a foundational system developed by Caltech faculty, to create de novo peptides incorporating non-canonical amino acids. Operating across the pharmaceutical sector, the firm advances an internal pipeline of gut-restricted and systemic oral biologics while licensing its precision medicine technology to global biopharma partners. The organization recently emerged from stealth operations after securing $13 million in Series A venture funding led by Madrona to advance its peptide design capabilities. The company's strategic direction is guided by a board of directors that includes Tom Bumol and Chris Picardo, alongside scientific advisory board members Mark DePristo and Michael Kay. Aizen Therapeutics was founded by Ajay Kshatriya, Bernhard Geierstanger, and Todd Peterson.
Aizen Therapeutic has raised $13.0M across 1 funding round.
Aizen Therapeutic has raised $13.0M in total across 1 funding round.
Aizen Therapeutics is an AI-driven biotechnology company developing Mirror Peptides, a novel class of synthetic, fully D-amino acid biologic medicines designed for superior therapeutic stability and reduced immunogenicity.[1][2][3][4] These peptides target diseases in neurological disorders, solid tumor cancers, and genetic diseases, leveraging the proprietary DaX™ platform—a generative AI-powered protein design tool created by Caltech Professor David Van Valen, MD, PhD—for rapid design-build-test cycles of about 4 weeks with high hit rates.[1][2][4][5] Based in San Diego, CA, Aizen emerged from stealth in November 2024 with $13 million in seed funding from investors like Wilson Hill, Madrona, and Cercano, advancing an early-stage pipeline from discovery through IND-enabling studies.[3][4][5]
The company serves patients with hard-to-treat conditions by addressing limitations of natural peptides, such as poor stability against proteases and unwanted immune responses, through mirror-image structures that evade these issues while maintaining binding efficacy to clinically relevant targets like transmembrane receptors.[1][4][5]
Aizen Therapeutics spun out of Caltech Professor David Van Valen, MD, PhD's lab in 2024, harnessing his pioneering work on the DaX™ platform for AI-driven design of Mirror Peptides.[1][2][3][5] Van Valen, the scientific founder, developed the structure-based model using generative AI, guided diffusion, and computational binding to unlock D-amino acid peptides—a vast chemical space beyond natural L-amino acids.[4][5]
Ajay Kshatriya, CEO and co-founder, leads alongside Todd Peterson (Chairman and co-founder) and a leadership team including Luke Ursell (VP Business Development), supported by a Scientific Advisory Board with experts like Michael Kay and Anil Bagri.[1] The idea emerged amid a "renaissance for peptide therapeutics," fueled by successes in areas like weight-loss drugs, with Aizen's stealth exit and $13M funding in November 2024 marking its pivotal launch into neuroscience and oncology programs.[3][5]
Aizen rides the wave of AI-enabled drug discovery, building on 2024 Nobel Prize-winning protein structure prediction advances to pioneer mirror-image biologics in a booming peptide therapeutics market—exemplified by GLP-1 drugs for weight loss.[5][7] Timing is ideal amid surging demand for stable, orally bioavailable peptides that hit the "sweet spot" of receptor targeting and tissue penetration, countering market forces like protease instability and immunogenicity that limit existing modalities.[4][5]
By unlocking D-amino acid space, Aizen influences the ecosystem through faster, more efficient R&D, potential partnerships (via partnering@aizentx.com), and whitepapers educating on Mirror Peptide history, accelerating biotech innovation in oncology and neuroscience.[1][4]
Aizen is poised to advance its pipeline into clinical stages, with DaX™ enabling expansion beyond neuroscience and tumors into more indications via optimized peptides for targeting and delivery.[1][4] Trends like generative AI maturation, compute scaling, and peptide market growth (projected to expand with oral biologics) will propel efficiency gains and collaborations.[2][5][7] Its influence may evolve from stealth innovator to ecosystem leader, potentially reshaping drug stability standards and drawing big pharma interest—extending the AI-driven biotech frontier pioneered in Van Valen's lab.[3][5]
Aizen Therapeutic has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2024 | $13M Seed | — | Digitalis Ventures, Madrona Venture Group, Scalebridge Capital, TWO Sigma Ventures, What IF Ventures | Announced |
Aizen Therapeutic has raised $13.0M in total across 1 funding round.
Aizen Therapeutic's investors include Digitalis Ventures, Madrona Ventures, Scalebridge Capital, Two Sigma Ventures, What If Ventures.
